Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome (Nasdaq: IMNM) announced that its Compensation Committee granted inducement awards to 14 new employees on October 31, 2024. The awards consist of non-statutory stock options to purchase 378,800 shares of common stock under the Company's 2024 Inducement Plan. The options have an exercise price of $11.47 per share, matching the Company's closing price on October 31. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months, contingent on continued employment.
Immunome (Nasdaq: IMNM) ha annunciato che il suo Comitato di Compensazione ha concesso premi di induzione a 14 nuovi dipendenti il 31 ottobre 2024. I premi consistono in opzioni su azioni non statutarie per l'acquisto di 378.800 azioni di azioni ordinarie nell'ambito del Piano di Induzione 2024 della Società. Le opzioni hanno un prezzo di esercizio di $11.47 per azione, corrispondente al prezzo di chiusura della Società del 31 ottobre. Le opzioni matureranno in quattro anni, con il 25% che matura dopo un anno e il restante che matura mensilmente per 36 mesi, a condizione di continuare l'impiego.
Immunome (Nasdaq: IMNM) anunció que su Comité de Compensación otorgó premios de inducción a 14 nuevos empleados el 31 de octubre de 2024. Los premios consisten en opciones sobre acciones no estatutarias para comprar 378,800 acciones comunes bajo el Plan de Inducción 2024 de la Compañía. Las opciones tienen un precio de ejercicio de $11.47 por acción, igualando el precio de cierre de la Compañía del 31 de octubre. Las opciones se consolidarán en un plazo de cuatro años, con un 25% consolidándose después de un año y el resto consolidándose mensualmente durante 36 meses, condicionado a la continuación del empleo.
Immunome (Nasdaq: IMNM)은 2024년 10월 31일에 보상 위원회가 14명의 신입 직원에게 유인 보상을 수여했다고 발표했습니다. 이 보상은 378,800주의 보통주를 구매할 수 있는 비상법 주식 옵션으로 구성되어 있으며, 회사의 2024년 유인 계획에 따라 이루어집니다. 옵션의 행사가는 $11.47 주당으로, 10월 31일 회사의 종가와 일치합니다. 옵션은 4년에 걸쳐 행사되며, 1년 뒤에 25%가 행사되고 나머지는 36개월 동안 매달 행사됩니다. 이는 고용을 계속하는 조건에 따릅니다.
Immunome (Nasdaq: IMNM) a annoncé que son Comité de Rémunération a accordé des primes d'incitation à 14 nouveaux employés le 31 octobre 2024. Les primes consistent en des options d'achat d'actions non statutaires pour acquérir 378 800 actions ordinaires dans le cadre du Plan d'Incitation 2024 de la Société. Les options ont un prix d'exercice de 11,47 $ par action, correspondant au prix de clôture de la Société au 31 octobre. Les options seront acquises sur une période de quatre ans, avec 25 % acquises après un an et le reste acquises mensuellement pendant 36 mois, sous réserve de la poursuite de l'emploi.
Immunome (Nasdaq: IMNM) gab bekannt, dass sein Vergütungsausschuss am 31. Oktober 2024 Incentive-Prämien für 14 neue Mitarbeiter genehmigt hat. Die Prämien bestehen aus nicht-statutarischen Aktienoptionen zum Kauf von 378.800 Aktien im Rahmen des Unternehmensplans für 2024. Die Optionen haben einen Ausübungspreis von $11,47 pro Aktie, was dem Schlusskurs des Unternehmens am 31. Oktober entspricht. Die Optionen werden über vier Jahre ausgeübt, wobei 25 % nach einem Jahr fällig werden und der Rest monatlich über 36 Monate fällig wird, vorausgesetzt, das Arbeitsverhältnis wird fortgesetzt.
- Company strengthens workforce with 14 new employees
- Stock-based compensation aligns employee interests with shareholders
- Potential shareholder dilution from 378,800 new stock options
Each stock option has an exercise price equal to
About Immunome
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugates (ADCs). In addition to a portfolio of discovery-stage ADCs, our pipeline includes AL102, a gamma secretase inhibitor currently in a Phase 3 trial for treatment of desmoid tumors, as well as IM-1021, a ROR1 ADC, and IM-3050, a FAP-targeted radioligand, both of which are the subject of INDs expected to be submitted in the first quarter of 2025. For more information, visit www.immunome.com.
Cautionary Statement Regarding Forward-Looking Statements
Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include Immunome’s expectations regarding progress of its pipeline and timeline for regulatory filings; and other statements regarding forecasts for the future. These forward-looking statements are based on Immunome’s current expectations and involve assumptions that may never materialize or may prove to be incorrect; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, the risks and uncertainties described in Immunome’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 12, 2024, and in Immunome’s other filings with the SEC. Except as required by law, Immunome assumes no obligation and does not intend to update any forward-looking statements included in this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241101678965/en/
Investor Contact
Max Rosett
Chief Financial Officer
investors@immunome.com
Source: Immunome, Inc.
FAQ
How many shares were granted in Immunome's (IMNM) October 2024 inducement awards?
What is the exercise price for Immunome's (IMNM) October 2024 inducement stock options?
What is the vesting schedule for Immunome's (IMNM) October 2024 inducement grants?
